Drugmakers are losing crucial friends on Capitol Hill

Six key pharma-friendly lawmakers will likely have left Capitol Hill by the beginning of 2025, presenting a challenge for the drug industry.

July 9, 2024 Check out STAT+

Sponsored By

Illustration: Christine Kao/STAT; Photos: Getty, Wikimedia Commons STAT+ | Drugmakers are losing crucial friends on Capitol Hill Six pharma-friendly lawmakers will likely not be on Capitol Hill in 2025. Experts say their replacements may not be as receptive to drug industry lobbying. By Rachel Cohrs Zhang STAT+ | FTC report finds PBMs profit at the expense of patients and independent pharmacies The FTC, in a report released Tuesday, says the big PBMs exercise significant control over which drugs are available, their price and access to them. By Ed Silverman STAT+ | Mikael Dolsten, Pfizer CSO who could take on Covid but not Wall Street, to step down Dolsten helped Pfizer outrace Moderna in the bid to develop a Covid vaccine but struggled to deliver on the expectations of its investors. By Matthew Herper Jovelle Tamayo for STAT The untold story of the Human Genome Project: How one man's DNA became a pillar of genetics An investigation by Undark tells the behind-the-scenes story of the Human Genome Project — changed plans, time pressures, and ethics concerns. By Ashley Smart — Undark STAT+ | A faster, simpler, cheaper cancer cell therapy is about to be tested in humans CAR-Ts can cure some blood cancers but are difficult to produce. A new study will test if a simple infusion could make it available for all. By Jason Mast STAT+ | Opinion: Private equity and neuroscience: a novel approach to developing new treatments for neurological disorders First Opinion essay: Recent deals involving Karuna Therapeutics, Cerevel Therapeutics show market opportunities for private equity in neurological field. By Bruce Leuchter Spencer Platt/Getty Images Opinion: Everyone deserves addiction treatment that works — including those in jail Providing addiction treatment in prisons and jails benefits public safety and helps reduce the burden on the wider health care system. By Nora D. Volkow and Tisha Wiley

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Daily Recap? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser